Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4610 The last 10 years – Single centre experience of gastrointestinal NEN

Introduction: Neuroendocrine neoplasms (NEN) are rare and heterogeneous, comprising 2% of all malignancies, with progressively increasing incidence. Most arise sporadically and the most frequent primary sites are gastrointestinal and lung.

Conference:

Presenting Author:

Authors: Corrêa Figueira C, Alves H, Bento A, Oliveira M, Garrido R,

Keywords: Neuroendocrine neoplasm, Gastrointestinal neuroendocrine tumour, Multidisciplinary team meeting, Retrospective, Single centre,

Introduction: SDHB pathogenic variants predispose to aggressive and metastatic paragangliomas (mPGLs). International consensus recommends temozolomide treatment (low-grade evidence). Capecitabine and temozolomide (CAPTEM) has shown advantage over temozolomide in the treatment of neuroendocrine tumours (NETs). Evidence for its use in mPGLs remains scarce.

Conference:

Presenting Author: G. Martins R

Authors: Silva L, Martins R, Couto J, Garcia R, Martins Fernandes A,

Keywords: mPGL, SDHB, captem,

#4149 A case of multiple endocrine neoplasia type 1 (MEN1) phenotype caused by CDC73 mutation

Introduction: CDC73 gene, also known as HRPT2 gene, its related diseases (CDC73-Related Disorders) mainly include hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid adenocarcinoma, familial isolated hyperparathyroidism (FIHP), which is autosomal dominant inheritance.

Conference:

Presenting Author: Tan H

Authors: Tan H, Chi Y,

Keywords: CDC73, HPT-JT, PNET, phenotype,

#4146 Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

Introduction: Limited therapeutic options are available for patients with advanced neuroendocrine neoplasms (NENs). Cabozantinib (CBZ), a tyrosine kinase inhibitor including c-MET pathway, and Temozolomide (TMZ), an alkylating agent enhancing the anti-angiogenic effect of CBZ, are emerging as promising treatments in NENs.

Conference:

Presenting Author:

Authors: Tornesello M, Starita N, Clemente O, Cerasuolo A, Bracigliano A,

Keywords: cabozantinib, temozolomide, neuroendocrine tumor, cell lines, in vitro study,

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,